Registry for patients with undifferentiated connective tissue disease
Official title: Undifferentiated Connective Tissue Disease Registry
Run by Hospital for Special Surgery, New York · NCT02234388 · Data updated 2026-11-12
This study is collecting information from patients with undifferentiated connective tissue disease to better understand their condition and how it may develop into more specific diseases.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Hospital for Special Surgery, New York Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | March 2012 |
| Main results expected | March 31, 2027 |
| Study ends | March 31, 2027 |
| Registry record updated | February 12, 2026 |
| Trial ID | NCT02234388 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients under the care of an HSS rheumatologist with specific autoantibody profiles and symptoms indicative of connective tissue disease.
✕Probably not a fit
Patients with well-defined connective tissue diseases or those under 18 years old may not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry aims to collect and analyze clinical and emotional data from patients diagnosed with undifferentiated connective tissue disease (UCTD). By gathering information from medical records, clinical histories, and patient-reported symptoms, the registry seeks to enhance understanding of UCTD and its progression to more defined connective tissue diseases. The data collected will be stored for future research studies, which will be overseen by the Institutional Review Board at the Hospital for Special Surgery. Participation is open to patients receiving care at HSS for UCTD.
Why it matters
Potential benefit: If successful, this registry could lead to improved prognostic predictions and better management strategies for patients with undifferentiated connective tissue disease.
How similar studies have gone: Other studies utilizing registries for autoimmune diseases have shown success in improving patient outcomes and understanding disease progression.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient under the care of an HSS rheumatologist * Positive ANA or a positive anti-ds DNA, anti-Ro/SS-A or other autoantibody on 2 or more occasions at least 12 weeks apart * One or more signs or symptoms of connective tissue disease, including but not limited to arthralgia, arthritis, myalgia, rash, sicca symptoms, pericarditis, pleuritis, pulmonary symptoms, peripheral neuropathy, photosensitivity, alopecia, oral or nasal ulcers, leucopenia, anemia, and abnormal nailfold capillaroscopy Exclusion Criteria: * Patients who meet criteria for well defined CTD including SLE, rheumatoid arthritis, polymyositis or dermatomyositis, systemic sclerosis, or antiphospholipid syndrome * Patients who are less than 18 * Those unable to give informed consent in English
Where it's running
-
Hospital for Special Surgery
New York, New York, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Suzetrigine for pain relief after knee replacement
This trial tests whether suzetrigine can reduce opioid use after a total knee replacement compared with placebo.
-
Wearing a straight knee brace for 10 days after revision knee replacement to improve motion.
This trial tests whether wearing a straight knee brace for 10 days after aseptic revision knee replacement helps people regain better knee motion at 3 months compared with standard physical therapy.
-
AI-simplified versus original patient education materials for parents of children with osteogenesis imperfecta
This tests whether AI-simplified educational materials help parents of children with osteogenesis imperfecta understand the condition better than the original materials.
-
Suzetrigine for pain control after primary total hip replacement
This will test whether taking Suzetrigine before surgery and for seven days afterward reduces opioid use and improves pain control in adults having a primary total hip replacement.
-
TAVNEOS for ENT symptoms in GPA
This study tests whether adding avacopan to standard care can help people with granulomatosis with polyangiitis who have active ear, nose, and throat symptoms.
-
ONT01 for Lupus Nephritis and Systemic Lupus Erythematosus
We will test whether ONT01 is safe and helps adults with lupus nephritis or active SLE when added to standard medicines like mycophenolate.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.